Related Experiment Video
Updated: May 4, 2026

09:41
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
12.4K
Plaque morphea with neurological involvement—an extraordinary uncommon presentation
Cristina Rosario1, Daniela Garelick, Gahl Greenberg
1Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel, tina.rosario@gmail.com.
Clinical Rheumatology
|December 20, 2013
Summary
Localized scleroderma, typically skin-limited, can present with rare neurological issues like seizures in morphea subtype. This case highlights a potential systemic autoimmune basis for localized scleroderma.
Area of Science:
- Dermatology
- Neurology
- Autoimmune Diseases
Background:
- Localized scleroderma (LS) traditionally affects skin, subcutaneous tissue, and bone.
- Craniofacial LS subtypes are known to involve the nervous system.
- Systemic manifestations in LS are increasingly recognized but rare in non-craniofacial subtypes.
Observation:
- A rare case of localized scleroderma en plaque (morphea) on the upper trunk and neck is presented.
- The patient experienced neurological manifestations in the form of seizures.
- Brain MRI revealed focal lesions contralateral to the skin lesions.
Findings:
- This case demonstrates an unusual association between morphea and neurological symptoms.
- The findings suggest that localized scleroderma may stem from a systemic autoimmune process.
- Neurological involvement in LS, though rare, warrants further investigation.
Implications:
- This case underscores the importance of considering systemic autoimmune processes in localized scleroderma.
- It may prompt further research into the pathogenesis of localized scleroderma and its potential systemic effects.
- Highlights the need for comprehensive evaluation in patients with atypical localized scleroderma presentations.
Related Concept Videos
Multiple Sclerosis l: Introduction
20
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
20
Neural Regulation
34.8K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
34.8K
Encephalitis l: Introduction
15
Encephalitis is inflammation of the brain parenchyma, most often due to infections or autoimmune processes. It presents with neuropsychiatric features such as fever, altered mental status, behavioral changes, cognitive dysfunction, seizures, focal deficits, and sometimes autonomic instability. In some cases, the meninges are also involved, resulting in meningoencephalitis.Infectious CausesInfectious encephalitis is most commonly viral but can also result from bacterial, fungal, or parasitic...
15
Bacterial Meningitis I: Introduction
15
Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...
15
Myasthenia Gravis ll: Pathophysiology
53
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
53

